Compounds

1. A compound of formula (I):

wherein

A 1 represents 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl;

R 1 represents —N(R 2 )C(R 3 )(R 4 )CONHR 5

R 2 represents hydrogen or methyl;

R 3 represents hydrogen and R 4 represents hydrogen, methyl or hydroxymethyl, or R 3 and R 4 each represent methyl; and

R 5 represents hydrogen or methyl;

or a physiologically functional derivative thereof.

2. A compound according to claim 1 wherein A 1 represents 5-fluoro-2-methoxy-phenyl.

3. A compound according to claim 1 wherein R 1 represents

4. A compound which is selected from the group consisting of:

1-{[3-(4-{[(2R)-4-[5-fluoro-2-(methyloxy)phenyl]-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]amino}-6-methyl-1H-indazol-1-yl)phenyl]carbonyl}-D-prolinamide; and

a physiologically functional derivative thereof.

5. A compound which is:

1-{[3-(4-{[(2R)-4-[5-fluoro-2-(methyloxy)phenyl]-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]amino}-6-methyl-1H-indazol-1-yl)phenyl]carbonyl}-D-prolinamide.

6. A compound which is:

1-{[3-(4-{[(2R)-4-[5-fluoro-2-(methyloxy)phenyl]-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]amino}-6-methyl-1H-indazol-1-yl)phenyl]carbonyl}-D-prolinamide or a physiologically functional derivative thereof in crystalline form.

7. A method for the treatment of a human or animal subject with an inflammatory and/or allergic condition, which method comprises administering to said human or animal subject an effective amount of a compound as claimed in claim 1 , or a physiologically functional derivative thereof.

8. A pharmaceutical composition comprising a compound as claimed in claim 1 , or a physiologically functional derivative thereof, and optionally, in admixture with one or more physiologically acceptable diluents, carriers, or mixtures thereof.

9. A pharmaceutical composition according to claim 8 which further comprises another therapeutically active agent.

10. A process for the preparation of a compound of formula (I) as claimed in claim 1 , or a physiologically functional derivative thereof, comprising:

a) coupling of a carboxylic acid of formula (II):

wherein A 1 is as defined in claim 1 with an amine HN(R 2 )C(R 3 )(R 4 )CONHR 5 or

wherein R 2 , R 3 , R 4 and R 5 are as defined in claim 1 , or

b) coupling of a carboxylic acid of formula (II):

wherein A 1 is as defined in claim 1 with an amine HN(R 2 )C(R 3 )(R 4 )CO 2 H or D- or L-proline, followed by a second coupling with R 5 —NH 2 , wherein R 2 , R 3 , R 4 and R 5 are as defined in claim 1 .

11. A compound of formula (V):

wherein P 1 is an ester protecting group.

12. A compound of formula (X):

wherein P 1 is an ester protecting group.